本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场
审批编码：PP-BA-CN-4787
获批日期：2024 年 9 月 3 日
内容策划：郭青青
项目审核：曹欢
题图来源：礼医提供
参考文献
[1] van der Heijde D, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Dec;68(12):1811-8.
[2] De Cock D, et al The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist. Rheumatol Adv Pract. 2019 Aug 30;3(2):rkz035.
[3] Magrey M, Walsh JA, Flierl S, et al. The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of Disease. ACR Open Rheumatol. 2023 May;5(5):264-276.
[4] Eberhard A, Bergman S, Mandl T, et al. Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study. Arthritis Res Ther. 2021 Jun 14;23(1):169.
[5] Strand V, Deodhar A, Alten R, et al. Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors: Multinational Real-World Findings. J Clin Rheumatol. 2021 Dec 1;27(8):e446-e455.
[6] de Vlam K, Maksymowych WP, Gallo G, et al. Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial. Rheumatol Ther. 2024 Jun;11(3):691-707.
[7] Selmi C, Chimenti MS, Novelli L, et al. Pain in axial spondyloarthritis: role of the JAK/STAT pathway. Front Immunol. 2024 Feb 23;15:1341981.
[8] Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018 Jun;77(6):797-807.
[9] Minerbi, A. and Fitzcharles, M.-A. (2022). Clinical pain management in the rheumatic diseases. In Clinical Pain Management (eds M.E. Lynch, K.D. Craig and P.W. Peng).
[10] 依奇珠单抗说明书
[11] Zhu X, et al. Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Aug;11(4):1011-1022.
[12] Xue Y, et al. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. BioDrugs. 2024 Jan;38(1):145-156.
[13] Maksymowych WP, et al. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging. Rheumatology (Oxford). 2022 Nov 2;61(11):4324-4334.
[14] Garufi C, Mancuso S, Caruso L, et al. POS1358 PAIN AND CALCITONIN GENE-RELATED PEPTIDE REDUCTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BARICITINIB. Scientific Abstracts.
[15] Genovese MC, Kremer J, Zamani O, et al. Baricitinib in Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52. Supplementary Appendix
[16] Caporali R, et al. POS0682 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO bDMARDs: RESULTS FROM RA-BEYOND FOLLOWING 6.9 YEARS OF TREATMENT. Annals of the Rheumatic Diseases. 2022;81:617-618.
[17] Luo H, et al. Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy[J]. Cell Rep, 2019, 29(8):2384-2397.e5.
[18] Sun C, et al. IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines. Mol Med Rep. 2017 Jan;15(1):89-96.
[19] Deodhar AA, et al. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. BMC Rheumatol. 2021 Sep 20;5(1):35.
[20] Mease P, et al. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. Rheumatol Ther. 2019 Sep;6(3):435-450.
[21] Kong N, et al. POS0801 IXEKIZUMAB IMPROVES DISEASE ACTIVITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS IRRESPECTIVE OF BASELINE OBJECTIVE INFLAMMATION STATUS. Annals of the Rheumatic Diseases. 2024;83:895-896.
[22] Zou H, et al. AB0912 IXEKIZUMAB IMPROVES SPINAL PAIN, STIFFNESS, FUNCTION, AND MOBILITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS REGARDLESS OF BASELINE INFLAMMATION STATUS. Annals of the Rheumatic Diseases. 2024;83:1763-1764.
[23] Deodhar A, et al. Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program. J Rheumatol. 2023 Aug;50(8):1020-1028.
[24] 徐胜前,黄烽. 应重视中轴型脊柱关节炎的达标治疗[J]. 中华内科杂志,2019,58(10):705-708.
[25] van der Heijde D, et al. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years. J Rheumatol. 2022 Mar;49(3):265-273. supplements
[26] van der Heijde D, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018 Dec 8;392(10163):2441-2451.
[27] Papp KA, et al. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017 Dec;177(6):1537-1551.
[28] Romiti R, et al. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis. Br J Dermatol. 2019 Jul;181(1):202-203.
[29] Salaffi F, et al. Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis. Inflammopharmacology. 2022 Jun;30(3):1119-1128.
[30] Tóth L, et al. Janus Kinase Inhibitors Improve Disease Activity and Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 24,135 Patients. Int J Mol Sci. 2022 Jan 23;23(3):1246.
[31] Taylor PC, et al. Ther Adv Musculoskelet Dis. 2022 Aug 16;14:1759720X221114101.
[32] Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017 Apr;76(4):694-700.
[33] Taylor PC，et al. Association Between Patient-reported Pain and Achieving Remission or Low Disease Activity at 3 Months in Patients with Rheumatoid Arthritis From The RA-BE-REAL Study. 2024 EULAR Abstract#OP0086.
[34] Alten R, et al. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients. Rheumatol Ther. 2023 Dec;10(6):1575-1595.
[35] 中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J].中华内科杂志,2018,57(4):242-251.
[36] Takeuchi T, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. Ann Rheum Dis. 2019 Feb;78(2):171-178.
[37] Taylor PC, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343.
[38] Wu CY, et al. AB0455 BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POST-MARKETING SAFETY STUDY Annals of the Rheumatic Diseases 2023;82:1418.
[39] 巴瑞替尼说明书.
